DGAP-News: CEVEC Pharmaceuticals GmbH / Key word(s): Alliance/Miscellaneous
CEVEC and Paragon Bioservices enter into comprehensive collaboration to roll
out CAP(R) technologies in North America
06.06.2016 / 14:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
CEVEC and Paragon Bioservices enter into comprehensive collaboration to
roll out CAP(R) technologies in North America
- Agreement establishes Paragon as CEVEC's preferred partner for contract
development and manufacturing (CDMO) services in North America
- Companies will conduct coordinated marketing and business development
activities to establish CEVEC's CAP(R) technologies as a new standard
for gene therapy vector production
- Collaboration includes developing a scalable clinical production
process for AAV-based gene therapy vectors based on the CAP(R)GT
platform
Cologne, Germany and Baltimore, MD, USA, June 6th, 2016 - CEVEC
Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made
recombinant glycoproteins and gene therapy vectors and Paragon Bioservices,
Inc., a leader in the manufacturing of biopharmaceuticals and vaccines,
today announced that the companies signed a collaboration and license
agreement to jointly establish CEVEC's proprietary CAP(R) technologies as a
new industry standard for the scalable production of viral gene therapy
vectors in North America.
Under the terms of the agreement, CEVEC and Paragon will co-market CEVEC's
proprietary CAP(R) technologies-including both the CAP(R)GT expression
system for gene therapy and CAP(R)Go for glycoproteins-as well as Paragon's
capabilities and expertise regarding CAP(R)-based research and development
services in North America.
CEVEC will recommend that its licensees use Paragon as its preferred
partner for CDMO services in North America. Additionally, CEVEC and Paragon
will jointly develop and market scaled-up clinical production processes for
AV (adenovirus), AAV (adeno associated virus) and LV (lentivirus)-based
gene therapy vectors using the CAP(R)GT platform.
CEVEC will bring in its expertise regarding the evaluation and development
of selected CAP(R) cell lines, including the development of viral packaging
and producer cell lines. Paragon will provide CDMO services to CEVEC's
North American CAP(R) technology licensees, including manufacture of
CAP(R)GT-derived materials for use in preclinical studies, as well as in
phase I and phase II clinical trials.
Financial details of this agreement were not disclosed.
"This agreement is the next step in executing on our strategy and sets the
stage to roll out our CAP(R) technologies into the North American markets.
Paragon is a strong CDMO with a good track record," commented Frank Ubags,
Chief Executive Officer of CEVEC Pharmaceuticals GmbH. "The combination of
CEVEC's expertise with its increasingly recognized proprietary CAP(R)GT and
CAP(R)Go technologies and Paragon's capabilities in high-quality
biopharmaceutical process development and GMP production provides a timely
solution for industrial needs in fast-growing markets, such as the larger-
scale manufacture of viral vectors in gene therapy."
"At Paragon, we are always looking for new and innovative technologies that
provide clear competitive advantages and add significant value to our
service portfolio in the best interest of our customers," said Peter Buzy,
President of Paragon Bioservices, Inc. "We are excited at the potential of
expanding our breadth and depth of expertise and capabilities with
recombinant viral vectors and glycoproteins to continue to advance
transformative therapeutic approaches that can benefit from scalable and
efficient CAP(R)-based processes."
About CEVEC:
CEVEC is a center of expertise for the production of biopharmaceuticals
using a unique human cell-based expression system.
CAP(R)GT is a regulatory endorsed expression platform for scalable viral
vector production. CAP(R)GT suspension cells grow to high cell densities
and show a broad viral propagation spectrum. Gene therapy vectors such as
lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV) can be
produced at industrial scale. CAP(R)GT enables better scale-up and
competitive production costs when compared to adherent cell culture
systems.
CAP(R)Go enables the production of proteins previously out of reach. The
expression platform comprises a portfolio of glyco-optimized human
suspension cell lines for tailor made glycosylation of recombinant
proteins. The cells highly efficiently produce a broad range of difficult
to express glycoproteins and provide authentic human post-translational
modifications.
More information: www.cevec.com.
Follow CEVEC on LinkedIn.
About Paragon Bioservices, Inc.:
Paragon Bioservices is a private-equity backed contract development and
manufacturing organization (CDMO) whose focus is the development and
manufacturing of biopharmaceuticals. The company provides research
services, process development and cGMP manufacturing. Paragon functions as
a translational bridge-from the research bench through manufacturing of
APIs and finished drug product for Phase I/II clinical trials. Paragon's
aim is to build strong client partnerships for development and
manufacturing, focusing on transformative technologies, including oncology
immunotherapies (CAR-T cell therapies and oncolytic viruses), new
generation vaccines (VLPs) and gene therapies (AAV). Paragon's cGMP
facilities include microbial and mammalian suites, aseptic fill-finish and
fully-segregated virus facilities.
Contact:
<pre>
CEVEC Pharmaceuticals GmbH MC Services AG
Frank Ubags Anne Hennecke
Chief Executive Officer Public Relations
T.:+49 221 46020800 T.: +49 211 52925222
E.: ubags@cevec.com E.: anne.hennecke@mc-services.eu
www.cevec.com
Paragon Bioservices, Inc.
Media Contact
Kevin Sly
SVP Marketing & Commercial Strategy
T.: +1 (410) 975 4053
E.: ksly@paragonbioservices.com
www.paragonbioservices.com
</pre>
---------------------------------------------------------------------------
06.06.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
469317 06.06.2016
DGAP-News: CEVEC and Paragon Bioservices enter into comprehensive collaboration to roll out CAP(R) technologies in North America
| Source: EQS Group AG